Start exploring your own markets for free

🚀 Try for Free

AI Therapeutics

Light Search completed

Invite

Radar Tracking

Subspaces (4)

Drug Discovery Optimization

Biomarker Identification

Genomic Data Analysis

Drug Repurposing

Pending to review

Not sure yet

Interested

Not interested

Download list

Showing 104 results

Company	Fit assessment	Description	Subspaces	Tags	HQ Location	Founding Date	Employees	Total Funding Raised	Last Funding Event	Received on
Rosetta Omics	The company effectively leverages machine learning for biomarker identification and the development of new therapeutic strategies, enhancing personalized medicine in oncology.	Operator of a biotechnology company intended to unlock the road to precision medicine in oncology by tumor characterization via high-resolution proteomic profiling via the combined use of mass spectrometry imaging and machine learning algorithms. The company focuses on personalized medicine by offering patients the right treatment at the right time, especially for poor prognosis cancers like digestive cancers, enabling better patient management and saving billions of money for the healthcare systems.	Biomarker Identification	Light Search	France	2022	1 - 10		Non-Equity Assistance, May 1, 2024	Oct 14, 2024
Javelin Biotech	Javelin Biotech effectively leverages machine learning and pattern discovery to enhance drug discovery and expand therapeutic options.	Operator of a predictive drug discovery platform intended to make an enhanced prediction of the performance of drugs in humans. The company's platform brings the human-relevant in-vitro data and computational biology or data analytics to pre-clinical drug discovery teams by accelerating preclinical drug discovery and development by finding human-relevant targets, enabling biopharmaceutical companies to optimize ADME(T) and PD properties which improves drug discovery and approval of the same.	Drug Discovery Optimization	Light Search	Woburn (United States)	2018	11 - 50		Pre-Seed, January 1, 2019	Oct 14, 2024
Quibim	Quibim is a leader in medical imaging analysis, utilizing AI to enhance the detection of diseases and track treatment efficacy through quantitative imaging biomarkers. Their platform integrates multi-omics data and advanced algorithms to improve patient outcomes in various medical fields, including oncology and immunology.	Developer of a multi-omics analytical platform designed for turning imaging into a catalyst for precision health. The company designs and integrates regulatory-cleared medical devices to improve patient outcomes, positioning at the forefront of imaging biomarkers in life sciences and clinical care and pioneers advanced algorithms to convert imaging data into actionable predictions, enabling the healthcare industry to improve the precision and effectiveness of patient care.	Biomarker Identification	Light Search	Spain	2015	51 - 200	$19.59M	Seed, April 2, 2024	Oct 14, 2024
51YunJian	Yunjian leverages machine learning and big data to discover disease markers and expand therapeutics, demonstrating a strong fit for the requirements.	Developer of a platform based on protein and metabolomic marker discovery technologies. The company focuses on applying innovative multi-omics and artificial intelligence technologies to the screening, diagnosis and treatment of diseases, providing clients with products and services such as early screening of chronic diseases and cancer, medication guidance, recurrence monitoring, and new tumor drug research and development.	Biomarker Identification	Light Search	Shanghai (China)	2015	11 - 50	$1.29M	Series B, August 19, 2022	Oct 14, 2024
Flagship Biosciences	Flagship Biosciences leverages machine learning for data analysis, discovers new patterns in biomarker data, and supports drug development, enhancing therapeutic options.	Developer of a drug development platform designed to apply computational tissue to biomarkers. The company's platform leverages the benefits of tissue-based biomarkers while reducing the risk and time associated with relying on a pathology-based patient selection strategy by integrating wet assay and image analysis to understand the biological content that determines patient phenotype and drug response, enabling drug developers to access advanced technology and scientific strategy to accelerate their drug approval by providing the necessary context.	Biomarker Identification	Light Search	United States	2009	51 - 200	$20.29M	Venture - Series Unknown, $5.00M, April 16, 2024	Oct 14, 2024
Meliora Therapeutics	Meliora Therapeutics leverages machine learning to discover new drug mechanisms and expand therapeutic options, optimizing the drug discovery process.	Operator of a next-generation biotech company intended to develop life-saving cancer therapies using machine learning. The company uses a proprietary prediction atlas mapping drug mechanism to identify the true MOA of molecules of interest cutting out a large and expensive phase of time, enabling researchers to ramp up the drug development process.	Drug Discovery Optimization	Light Search	San Francisco (United States)	2021	11 - 50	$11.00M	Seed, $11.00M, September 29, 2022	Oct 14, 2024
DeepThink Health	DeepThink Health leverages machine learning to discover patterns and expand therapeutics, while effectively analyzing genomic data.	Developer of an innovative precision intelligence platform which captures and structures large clinical and genomic datasets based in Richmond, California. The company applies advanced analytics and machine learning to enable the practice of precision medicine and the discovery of new patient treatments, allowing advance precision medicine and enabling novel discoveries.	Genomic Data Analysis	Light Search	United States	2018	11 - 50		NA	Oct 14, 2024
converger.ai	Converger.ai leverages machine learning and data analytics to discover patterns in genetics and expand therapeutic approaches for disease prevention and treatment.	We are a biotechnology company that uses novel analytics to unlock the secrets of human genetic diversity, helping prevent, diagnose and treat disease.	Genomic Data Analysis	Light Search	Johannesburg (South Africa)	2023	1 - 10	$205.13K	Pre-Seed, $200.00K, June 20, 2023	Oct 14, 2024
AliveX	AliveX effectively utilizes machine learning for pattern discovery and therapeutic expansion, with a strong focus on biomarker identification.	Developer of an AI-driven immunology platform designed to focus on biomarker discovery. The company's platform combines multi-omics data, AI, and computational biology to decode the human immune system, enabling immunologists, molecular biologists, and clinical experts to solve the most pressing clinical challenges, and transform life sciences research and develop diagnostics.	Biomarker Identification	Light Search	Australia	2019	51 - 200		Seed, June 22, 2021	Oct 14, 2024
BioAI Health	BioAI Health effectively utilizes machine learning for pattern discovery and therapeutic expansion, focusing on biomarker identification to enhance personalized medicine.	Developer of a multi-modal AI platform intended to analyze scalable information and customize services for biopharma clinical biomarker development and diagnostics. The company's platform is based on technologies and services that integrate complex data sets from translational studies and clinical trials to develop machine learning models on multi-omic data, enabling the pharma industry to predict patient response to therapy and drug resistance and solve major challenges in research and development.	Biomarker Identification	Light Search	Goffstown (United States)	2020	11 - 50	$3.50M	Seed, $500.00K, April 5, 2024	Oct 14, 2024